Renal

Localized

T1b or greater (has not spread beyond the kidney)

IRB#16576
Atezolizumab vs placebo as adjuvant therapy following nephrectomy

IRB#16300
Merck 3475

No Prior Systemic Therapy

Clear Cell

Matasactectomy Candidate

IRB#9241
Pazopanib vs. Placebo in Patients with mRCC

Cytoreductive Nephrectomy Candidate

No trials Currently Available

Prior Systemic Therapy

IRB# 11283
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a Lead-In Phase IB Dose-Escalation Portion) In Patients With Advanced Or Metastatic Renal Cell Carcinoma.

Non- Clear Cell

No Trials Currently Available

Metastatic/advanced

Key

Open for Enrollment

In Development

Enrollment on Hold

1/20/17

www.ohsu.edu/cancer